Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2019
SIETES contiene 92806 citas

 
 
<< anterior 21 a 40 de 327 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Hawkes N. Are new hepatitis C drugs all they’re cracked up to be?. BMJ 2017;357:j2961. [Ref.ID 101659]
22. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
24. Cita con resumen
Anónimo. Combination HCV therapy achieves high sustained viral response. DIA Daily 2016:5. [Ref.ID 100926]
25. Cita con resumen
Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]
30. Cita con resumen
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SB, Cho Y, Nadeau-Fredette A-C, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GFM. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 2016;316:313-24. [Ref.ID 100498]
31. Cita con resumen
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippi K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209-19. [Ref.ID 100399]
33. Cita con resumen
Anónimo. FDA approves new, targeted treatment for bladder cancer. U.S. Food and Drug Administration 2016:18 de mayo. [Ref.ID 100281]
34. Cita con resumen
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, Stewart R, McGuire P, Bhattacharyya S. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study . BMJ Open 2016;6:e009888. [Ref.ID 100279]
35. Cita con resumen
Anónimo. FDA Advisory Panel unanimously recommends approval of new liver drug. U.S. Food and Drug Administration 2016:2. [Ref.ID 100108]
36. Cita con resumen
Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen J, Buse JB, for the DUAL V Investigators. Effect of insulingGlargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes. The DUAL V randomized clinical trial. JAMA 2016;315:898-907. [Ref.ID 100023]
37. Cita con resumen
Boussageon R, Gueyffier F, Cornu C. Metformin as firstline treatment for type 2 diabetes: are we sure?. BMJ 2016;352:h6748. [Ref.ID 99967]
38. Cita con resumen
Anónimo. FDA approves drug to treat multiple myeloma. DIA Daily 2015:17 de noviembre. [Ref.ID 99644]
39. Cita con resumen
Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Ahrén B, Torffvit O, Attvall S, Ekelun M, Filipsson K, Tengmark B-O, Sjöberg S, Pehrsson N-G. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ 2015;351:h5364. [Ref.ID 99640]
40. Cita con resumen
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]
Seleccionar todas
 
<< anterior 21 a 40 de 327 siguiente >>